Melinda L Telli, MD

Medicare standing: Clear; Enrolled, allowed to bill and order, not excluded
Plans that list them: 17; 3 carriers
Office: 1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Telli’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
SCAN Balance (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Classic (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN MyChoice (HMO)	SCAN Health Plan	Listed	Oct 3, 2026
SCAN Strive (HMO C-SNP)	SCAN Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence A84689 · Current

Licensed to practise in California · since 2003 · expires 2027-09-30 · George Washington University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024

See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Stanford Health Care

Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	5.31 (4.24 to 6.37) · 8,661 cases	Worse	Jul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	14.1 (12.7 to 15.7) · 2,191 cases	Worse	Jan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths	4.08 (1.95 to 6.21) · 5,296 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.317	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.446	Better	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.241	Better	Oct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.7 (0.6 to 0.9) · 3,348 cases	Better	Jan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths	1.06 (0.45 to 1.67) · 5,374 cases	No different	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.86 (0.72 to 1)	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	166.09 (137.88 to 194.3) · 470 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	1.1 · 192 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	6.4 · 146 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	9.7 · 253 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	6.3 · 880 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	10.3 · 935 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.7 · 501 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.1 · 7,730 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.13 (0 to 0.27) · 20,799 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.28 (0.14 to 0.43) · 23,182 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.94 (0.2 to 1.68) · 5,694 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	2.36 (1.54 to 3.19) · 7,846 cases	No different	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	5.2 (3.76 to 6.64) · 5,603 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	1.38 (0.23 to 2.53) · 2,211 cases	No different	Jul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths	0.52 (0.21 to 0.83) · 19,915 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.6 · 416 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.869	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.857	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0.368	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	16.2 · 247 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	20.5 · 1,021 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	47.8 · 258 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-1.6 · 990 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	20.8 · 976 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	16.5 · 959 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	5.2 (4.4 to 6.2) · 2,191 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.1 · 425 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	9.6 · 158 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	19.6 · 183 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	12.7 (10.4 to 15.4) · 4,578 cases	No different	Jan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Sort by

Patient survey stars by topic at Stanford Health Care

Cleanliness	4
Nurse communication	4
Doctor communication	4
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	2
Recommend hospital	5

Sort by

Share of patients giving the best answer at Stanford Health Care

Room was "always" clean	75%
Nurses "always" communicated well	82%
Doctors "always" communicated well	81%
Staff "always" explained	63%
Yes, staff "did" give patients this information	89%
Yes, staff "did" give patients information about help after discharge	89%
Doctors "always" explained things so they could understand	76%
Doctors "always" listened carefully	80%
Doctors "always" treated them with courtesy and respect	87%
Patients who gave a rating of "9" or "10" (high)	79%
Staff "always" explained new medications	76%
Nurses "always" explained things so they could understand	77%
Nurses "always" listened carefully	79%
Nurses "always" treated them with courtesy and respect	88%
"Always" quiet at night	53%
"YES", patients would definitely recommend the hospital	83%
Staff "always" explained possible side effects	50%
Yes, staff "did" give patients information about possible symptoms	90%

Original Medicare doctor bills

$46,759

Medicare paid this office $46,759 for 107 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	55	$25,456	$130
Long return visit (40+ min)	25	$5,893	$147
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	13	$5,642	$106
New patient visit (60+ min)	15	$2,447	$163
Return visit (30+ min)	23	$2,338	$83

See all 6 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	55	$25,456	$130
Long return visit (40+ min)	25	$5,893	$147
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	13	$5,642	$106
New patient visit (60+ min)	15	$2,447	$163
Return visit (30+ min)	23	$2,338	$83
Hospital discharge day management, more than 30 minutes	12	$1,259	$105

Who their Medicare patients are

107 Original Medicare patients in 2024. Average age 72 · Women 88% · Also on Medicaid 19% · Health risk score 2.17. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 53% · Diabetes 21% · Chronic kidney disease 21% · Coronary heart disease 18% · Depression 18% · Heart failure 14% · Atrial fibrillation 14% · COPD 12% · Stroke 10%.

The office billed $129,550, Medicare allowed $59,256 and paid $46,759; for 376 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	107	376	72	2.17	$129,550	$46,759
2023	103	325	72	1.79	$110,063	$38,977
2022	83	276	73	1.86	$94,152	$29,716
2021	92	332	72	2.20	$105,664	$36,677
2020	114	406	72	1.91	$135,534	$38,819
2019	131	402	72	2.22	$87,123	$36,537
2018	130	377	72	1.80	$72,081	$33,884
2017	91	207	72	1.90	$54,961	$18,882
2016	173	448	71	1.98	$128,169	$40,951
2015	146	375	71	2.03	$102,074	$32,588
2014	171	498	71	1.51	$134,102	$42,388
2013	135	409	71	1.35	$108,898	$35,588

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	61	$23,235	$132
New patient visit (60+ min)	27	$4,530	$168
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$1,919	$160
Return visit (30+ min)	14	$1,468	$86
Hospital discharge day management, more than 30 minutes	13	$1,392	$107
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	16	$725	$29

2022: 4 services

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	43	$15,672	$126
New patient visit (60+ min)	21	$3,609	$172
Initial hospital care with moderate level of medical decision making at least 75 minutes	14	$2,570	$171
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	24	$1,414	$29

2021: 6 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	47	$21,061	$131
Return visit (30+ min)	41	$4,597	$79
New patient visit (60+ min)	21	$3,618	$172
Initial hospital care with moderate level of medical decision making at least 75 minutes	13	$2,452	$189
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	11	$2,100	$95
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	17	$1,049	$30

2020: 7 services

Sort by

Original Medicare services billed in 2020

Return visit (30+ min)	52	$12,881	$73
Long return visit (40+ min)	30	$9,044	$106
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	22	$4,969	$97
Initial hospital care with moderate level of medical decision making at least 75 minutes	20	$4,053	$193
New patient visit (60+ min)	16	$2,508	$157
Hospital discharge day management, more than 30 minutes	18	$1,926	$101
Short return visit (20+ min)	11	$523	$44

2019: 7 services

Sort by

Original Medicare services billed in 2019

Return visit (30+ min)	61	$10,960	$70
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	31	$8,112	$94
Long return visit (40+ min)	32	$7,269	$100
Initial hospital care with moderate level of medical decision making at least 75 minutes	24	$4,405	$184
New patient visit (60+ min)	14	$2,132	$152
Hospital discharge day management, more than 30 minutes	15	$1,487	$99
Short return visit (20+ min)	12	$604	$46

2018: 7 services

Sort by

Original Medicare services billed in 2018

Return visit (30+ min)	68	$11,124	$68
Long return visit (40+ min)	37	$8,679	$99
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	14	$4,868	$94
Initial hospital care with moderate level of medical decision making at least 75 minutes	20	$3,820	$182
New patient visit (60+ min)	18	$2,709	$151
Hospital discharge day management, more than 30 minutes	12	$1,185	$99
Short return visit (20+ min)	12	$599	$46

2017: 6 services

Sort by

Original Medicare services billed in 2017

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	17	$4,581	$93
Long return visit (40+ min)	26	$3,858	$88
Return visit (30+ min)	34	$3,386	$64
New patient visit (60+ min)	16	$2,405	$150
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$2,357	$181
Hospital discharge day management, more than 30 minutes	12	$1,178	$98

2016: 7 services

Sort by

Original Medicare services billed in 2016

Return visit (30+ min)	57	$10,786	$69
Long return visit (40+ min)	50	$9,513	$99
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	35	$7,674	$90
Initial hospital care with moderate level of medical decision making at least 75 minutes	23	$4,146	$180
New patient visit (60+ min)	22	$3,294	$150
Hospital discharge day management, more than 30 minutes	16	$1,556	$97
Short return visit (20+ min)	20	$911	$41

2015: 7 services

Sort by

Original Medicare services billed in 2015

Return visit (30+ min)	61	$10,869	$68
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	26	$5,478	$93
Long return visit (40+ min)	27	$4,737	$97
Initial hospital care with moderate level of medical decision making at least 75 minutes	24	$4,332	$181
New patient visit (60+ min)	18	$2,662	$148
Hospital discharge day management, more than 30 minutes	21	$2,047	$97
Short return visit (20+ min)	17	$818	$39

2014: 8 services

Sort by

Original Medicare services billed in 2014

Return visit (30+ min)	81	$13,698	$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	32	$8,133	$92
Long return visit (40+ min)	36	$6,565	$94
Initial hospital care with moderate level of medical decision making at least 75 minutes	29	$5,396	$180
New patient visit (60+ min)	25	$3,624	$145
Hospital discharge day management, more than 30 minutes	20	$1,931	$97
Short return visit (20+ min)	30	$1,410	$43
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	12	$1,281	$64

2013: 8 services

Sort by

Original Medicare services billed in 2013

Return visit (30+ min)	58	$9,373	$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	23	$5,495	$90
Long return visit (40+ min)	30	$5,060	$94
Return visit (30+ min)	35	$4,021	$87
Initial hospital care with moderate level of medical decision making at least 75 minutes	22	$3,880	$176
New patient visit (60+ min)	16	$2,200	$138
Hospital discharge day management, more than 30 minutes	15	$1,520	$95
Short return visit (20+ min)	16	$659	$39

Medicaid work

$4,591 in 2024

Medicaid paid $4,591 for 88 billed services this clinician did in 2024, up to 14 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	62	$2,766
1ST HOSP IP/OBS HIGH 75	14	$1,168
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter	12	$657

Sort by

Medicaid work by year

2024	88	3	14	$4,591
2023	40	3	14	$1,688
2022	13	1	12	$857
2021	42	1	18	$2,122
2019	32	1	17	$1,258
2018	14	1	12	$505

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Long return visit (40+ min)	13	$626
Return visit (30+ min)	12	$549
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter	15	$513

2022

Sort by

Largest Medicaid services in 2022

Long return visit (40+ min)	13	$857

2021

Sort by

Largest Medicaid services in 2021

Long return visit (40+ min)	42	$2,122

2019

Sort by

Largest Medicaid services in 2019

Return visit (30+ min)	32	$1,258

2018

Sort by

Largest Medicaid services in 2018

Return visit (30+ min)	14	$505

Drugs they prescribed that Part D paid

$166,596

Pharmacies billed $166,596 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

106 generic and 19 brand-name prescriptions · $166,596 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Letrozole	14	$323	$23

Year by year

Sort by

Part D prescribing by year

2024	125	37	None	15%	$166,596
2023	63	26	None	None	$123,666
2022	51	21	None	None	$50,780
2021	76	26	None	None	$2,928
2020	128	42	None	None	$202,575
2019	123	42	None	None	$150,693
2018	129	38	None	14%	$34,994
2017	117	46	None	9%	$48,502
2016	172	46	7% (12)	19%	$100,235
2015	281	74	None	14%	$109,793
2014	319	76	None	None	$74,689
2013	245	56	None	25%	$84,388

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2021: 1 drug

Sort by

Part D drugs prescribed in 2021

Ondansetron	11	$121	$11

2020: 1 drug

Sort by

Part D drugs prescribed in 2020

Anastrozole	15	$571	$38

2019: 1 drug

Sort by

Part D drugs prescribed in 2019

Anastrozole	11	$371	$34

2018: 1 drug

Sort by

Part D drugs prescribed in 2018

Anastrozole	29	$536	$18

2017: 2 drugs

Sort by

Part D drugs prescribed in 2017

Exemestane	19	$4,087	$215
Anastrozole	16	$200	$12

2016: 3 drugs

Sort by

Part D drugs prescribed in 2016

Exemestane	18	$3,684	$205
Anastrozole	43	$641	$15
Letrozole	14	$265	$19

2015: 4 drugs

Sort by

Part D drugs prescribed in 2015

Exemestane	46	$19,618	$426
Tamoxifen Citrate	35	$1,237	$35
Anastrozole	72	$1,213	$17
Letrozole	31	$802	$26

2014: 8 drugs

Sort by

Part D drugs prescribed in 2014

Exemestane	47	$22,672	$482
Aromasin	19	$11,252	$592
Arimidex	12	$5,282	$440
Anastrozole	51	$1,567	$31
Tamoxifen Citrate	35	$1,217	$35
Letrozole	18	$412	$23
Gabapentin	14	$219	$16
Lorazepam	16	$88	$6

2013: 6 drugs

Sort by

Part D drugs prescribed in 2013

Arimidex	25	$17,532	$701
Exemestane	40	$14,295	$357
Enoxaparin	19	$3,236	$170
Tamoxifen Citrate	31	$845	$27
Anastrozole	18	$580	$32
Lorazepam	12	$70	$6

Money from drug and device companies

$17,001 in 2025

Sort by

Industry payments by year

2025	8	24	$13,530	$17,001
2024	9	15	$9,540	$10,753
2023	7	18	$11,640	$12,430
2022	8	21	$18,116	$19,307
2021	8	17	$24,433	$25,812
2020	3	23	$7,740	$9,434
2019	5	52	$35,710	$42,511

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Eli Lilly and	None	$5,721	15 payments Meals · 2025-05-12 · $37 Meals · 2025-05-12 · $105 Travel · 2025-05-12 · $129 Meals · 2025-05-12 · $16 Consulting · 2025-05-06 · $2,700 Travel · 2025-04-28 · $398 Travel · 2025-04-28 · $803 Meals · 2025-04-28 · $54 Meals · 2025-04-28 · $59 Meals · 2025-04-28 · $16 Travel · 2025-04-28 · $257 Travel · 2025-04-28 · $444 Travel · 2025-04-28 · $347 Travel · 2025-04-28 · $347 Meals · 2025-04-28 · $9
F. Hoffmann-La Roche AG	Perjeta	$2,870	1 payment Consulting for Perjeta · 2025-06-06 · $2,870
Gilead Sciences	Trodelvy	$2,330	2 payments Consulting for Trodelvy · 2025-12-18 · $2,180 Meals for Trodelvy · 2025-12-11 · $150
Novartis Pharmaceuticals	Kisqali	$2,062	2 payments Meals for Kisqali · 2025-05-31 · $137 Consulting for Kisqali · 2025-05-31 · $1,925
AstraZeneca UK	Truqap	$2,055	1 payment Consulting for Truqap · 2025-04-22 · $2,055
Lilly USA	None	$1,800	1 payment Consulting · 2025-06-24 · $1,800

See all 24 published payments

Sort by

Every published payment

Gilead Sciences	Consulting · 2025-12-18	Trodelvy	$2,180
Gilead Sciences	Meals · 2025-12-11	Trodelvy	$150
Pfizer	Meals · 2025-10-17	None	$95
Lilly USA	Consulting · 2025-06-24	None	$1,800
F. Hoffmann-La Roche AG	Consulting · 2025-06-06	Perjeta	$2,870
Genentech USA	Meals · 2025-06-01	None	$68
Novartis Pharmaceuticals	Meals · 2025-05-31	Kisqali	$137
Novartis Pharmaceuticals	Consulting · 2025-05-31	Kisqali	$1,925
Eli Lilly and	Meals · 2025-05-12	None	$37
Eli Lilly and	Meals · 2025-05-12	None	$105
Eli Lilly and	Travel · 2025-05-12	None	$129
Eli Lilly and	Meals · 2025-05-12	None	$16
Eli Lilly and	Consulting · 2025-05-06	None	$2,700
Eli Lilly and	Travel · 2025-04-28	None	$398
Eli Lilly and	Travel · 2025-04-28	None	$803
Eli Lilly and	Meals · 2025-04-28	None	$54
Eli Lilly and	Meals · 2025-04-28	None	$59
Eli Lilly and	Meals · 2025-04-28	None	$16
Eli Lilly and	Travel · 2025-04-28	None	$257
Eli Lilly and	Travel · 2025-04-28	None	$444
Eli Lilly and	Travel · 2025-04-28	None	$347
Eli Lilly and	Travel · 2025-04-28	None	$347
Eli Lilly and	Meals · 2025-04-28	None	$9
AstraZeneca UK	Consulting · 2025-04-22	Truqap	$2,055

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $10,753

Sort by

Payments by company in 2024

Genentech USA	None	$3,872	2 payments Consulting · 2024-02-29 · $3,670 Meals · 2024-02-29 · $202
Daiichi Sankyo	None	$3,125	2 payments Consulting · 2024-03-13 · $1,250 Consulting · 2024-03-06 · $1,875
Merck Sharp & Dohme	None	$2,745	1 payment Consulting · 2024-12-04 · $2,745
Gilead Sciences	Trodelvy	$293	3 payments Meals · 2024-12-12 · $98 Meals · 2024-06-03 · $109 Meals for Trodelvy · 2024-05-15 · $86
AstraZeneca Pharmaceuticals LP	None	$286	2 payments Meals · 2024-06-03 · $36 Grant · 2024-01-31 · $250
AstraZeneca UK	None	$211	2 payments Meals · 2024-09-12 · $76 Meals · 2024-05-31 · $135
Pfizer	Ibrance	$106	1 payment Meals for Ibrance · 2024-05-16 · $106
BioNTech SE	None	$81	1 payment Meals · 2024-10-12 · $81
Genentech	Kadcyla	$34	1 payment Meals for Kadcyla · 2024-01-18 · $34

2023: $12,430

Sort by

Payments by company in 2023

AstraZeneca Pharmaceuticals LP	None	$6,129	6 payments Consulting · 2023-12-18 · $2,398 Meals · 2023-12-06 · $135 Consulting · 2023-07-05 · $1,028 Consulting · 2023-04-24 · $1,028 Consulting · 2023-03-10 · $514 Consulting · 2023-02-01 · $1,028
Merck Sharp & Dohme	None	$2,135	1 payment Consulting · 2023-12-18 · $2,135
Daiichi Sankyo	None	$2,075	2 payments Meals · 2023-12-06 · $44 Consulting · 2023-08-23 · $2,031
Stemline Therapeutics	Orserdu	$1,573	2 payments Consulting for Orserdu · 2023-09-29 · $1,480 Meals for Orserdu · 2023-08-17 · $93
Gilead Sciences	Trodelvy	$227	2 payments Meals for Trodelvy · 2023-11-14 · $104 Meals for Trodelvy · 2023-06-03 · $124
Pfizer	Ibrance	$193	4 payments Education for Ibrance · 2023-06-06 · $13 Meals for Ibrance · 2023-06-05 · $142 Meals for Ibrance · 2023-06-03 · $28 Education for Ibrance · 2023-05-24 · $10
Blueprint Medicines	None	$98	1 payment Meals · 2023-12-07 · $98

2022: $19,307

Sort by

Payments by company in 2022

AstraZeneca Pharmaceuticals LP	Enhertu	$8,964	13 payments Meals · 2022-12-10 · $108 Meals for Enhertu · 2022-12-10 · $115 Meals · 2022-12-10 · $124 Meals for Lynparza · 2022-12-07 · $34 Consulting for Enhertu · 2022-07-11 · $2,055 Consulting for Enhertu · 2022-07-03 · $4,795 Meals · 2022-06-06 · $135 Meals for Enhertu · 2022-06-06 · $92 Meals for Enhertu · 2022-05-27 · $88 Meals for Enhertu · 2022-05-26 · $23 Meals for Enhertu · 2022-05-16 · $25 Consulting for Enhertu · 2022-04-12 · $685 Consulting for Lynparza · 2022-02-09 · $685
GlaxoSmithKline	None	$3,349	2 payments Consulting · 2022-08-03 · $3,200 Meals · 2022-06-05 · $149
Daiichi Sankyo	Enhertu	$2,569	1 payment Consulting for Enhertu · 2022-10-12 · $2,569
Merck Sharp & Dohme	None	$1,525	1 payment Consulting · 2022-11-02 · $1,525
AstraZeneca UK	None	$1,370	1 payment Consulting · 2022-03-17 · $1,370
Blueprint Medicines	None	$1,232	1 payment Honoraria · 2022-12-21 · $1,232
G1 Therapeutics	Cosela	$182	1 payment Meals for Cosela · 2022-06-04 · $182
Pfizer	Ibrance	$116	1 payment Meals for Ibrance · 2022-06-06 · $116

2021: $25,812

Sort by

Payments by company in 2021

Genentech	Tecentriq	$7,500	1 payment Consulting for Tecentriq · 2021-04-27 · $7,500
AstraZeneca Pharmaceuticals LP	Lynparza	$4,488	2 payments Meals · 2021-12-09 · $36 Consulting for Lynparza · 2021-06-29 · $4,453
Merck Sharp & Dohme	Keytruda	$3,750	2 payments Consulting for Keytruda · 2021-03-17 · $1,250 Consulting for Keytruda · 2021-02-01 · $2,500
Genzyme	None	$3,270	1 payment Consulting · 2021-09-15 · $3,270
Pfizer	Ibrance	$2,001	2 payments Meals for Ibrance · 2021-12-08 · $111 Honoraria for Ibrance · 2021-01-08 · $1,890
Gilead Sciences	None	$1,902	2 payments Consulting · 2021-12-21 · $1,890 Education · 2021-06-01 · $12
Blueprint Medicines	None	$1,680	1 payment Honoraria · 2021-04-23 · $1,680
RefleXion Medical	Reflexion Medical Radiotherapy System	$1,221	6 payments Meals for Reflexion Medical Radiotherapy System · 2021-11-18 · $309 Gift for Reflexion Medical Radiotherapy System · 2021-11-18 · $108 Gift for Reflexion Medical Radiotherapy System · 2021-11-18 · $70 Travel for Reflexion Medical Radiotherapy System · 2021-11-18 · $305 Travel for Reflexion Medical Radiotherapy System · 2021-10-28 · $395 Travel for Reflexion Medical Radiotherapy System · 2021-10-28 · $35

2020: $9,434

Sort by

Payments by company in 2020

Eli Lilly and	None	$4,844	20 payments Travel · 2020-01-28 · $36 Consulting · 2020-01-28 · $3,150 Travel · 2020-01-28 · $24 Meals · 2020-01-17 · $2 Meals · 2020-01-17 · $10 Meals · 2020-01-17 · $19 Meals · 2020-01-17 · $42 Meals · 2020-01-17 · $2 Meals · 2020-01-17 · $1 Meals · 2020-01-17 · $5 Meals · 2020-01-17 · $3 Meals · 2020-01-17 · $6 Meals · 2020-01-17 · $2 Meals · 2020-01-17 · $4 Meals · 2020-01-17 · $5 Meals · 2020-01-17 · $19 Meals · 2020-01-17 · $22 Meals · 2020-01-17 · $11 Travel · 2020-01-17 · $265 Travel · 2020-01-16 · $1,218
Merck Sharp & Dohme	None	$2,700	2 payments Consulting · 2020-11-13 · $1,350 Consulting · 2020-07-29 · $1,350
Pfizer	Talzenna	$1,890	1 payment Honoraria for Talzenna · 2020-10-09 · $1,890

2019: $42,511

Sort by

Payments by company in 2019

Celgene	Abraxane	$16,368	12 payments Meals for Abraxane · 2019-11-16 · $5 Consulting for Abraxane · 2019-11-16 · $7,200 Meals for Abraxane · 2019-11-16 · $126 Travel for Abraxane · 2019-11-16 · $78 Travel · 2019-11-15 · $284 Travel for Abraxane · 2019-11-15 · $266 Travel for Abraxane · 2019-02-06 · $88 Meals for Abraxane · 2019-02-06 · $71 Consulting for Abraxane · 2019-02-02 · $7,450 Travel for Abraxane · 2019-02-02 · $294 Meals for Abraxane · 2019-02-02 · $132 Travel · 2019-02-01 · $375
Merck Sharp & Dohme	Keytruda	$13,569	17 payments Travel · 2019-12-06 · $300 Consulting for Keytruda · 2019-11-20 · $500 Travel · 2019-10-10 · $150 Consulting · 2019-10-10 · $4,300 Travel for Keytruda · 2019-10-01 · $177 Meals for Keytruda · 2019-10-01 · $28 Meals for Keytruda · 2019-10-01 · $59 Travel for Keytruda · 2019-09-30 · $334 Consulting for Keytruda · 2019-08-21 · $1,000 Travel · 2019-06-28 · $150 Consulting · 2019-06-28 · $5,650 Travel · 2019-06-22 · $436 Meals · 2019-06-22 · $55 Meals · 2019-06-22 · $60 Meals · 2019-06-22 · $65 Travel · 2019-06-21 · $239 Meals for Keytruda · 2019-06-01 · $67
Genentech USA	Tecentriq	$6,009	7 payments Meals for Tecentriq · 2019-06-28 · $257 Travel for Tecentriq · 2019-06-27 · $24 Meals for Tecentriq · 2019-06-27 · $73 Travel for Tecentriq · 2019-06-27 · $381 Travel for Tecentriq · 2019-06-27 · $94 Travel for Tecentriq · 2019-06-27 · $1,181 Consulting for Tecentriq · 2019-06-27 · $4,000
AbbVie	Venclexta	$3,602	11 payments Meals · 2019-12-17 · $18 Consulting · 2019-12-17 · $2,700 Travel · 2019-12-17 · $64 Meals for Venclexta · 2019-10-04 · $25 Travel for Venclexta · 2019-10-04 · $346 Meals for Venclexta · 2019-10-04 · $65 Meals for Venclexta · 2019-10-04 · $25 Meals for Venclexta · 2019-10-04 · $45 Travel for Venclexta · 2019-10-04 · $13 Travel for Venclexta · 2019-10-03 · $193 Meals for Venclexta · 2019-10-03 · $108
Pfizer	Bavencio	$2,963	5 payments Paid to speak or teach for Talzenna · 2019-10-01 · $620 Consulting for Bavencio · 2019-07-15 · $716 Consulting for Bavencio · 2019-06-10 · $954 Paid to speak or teach for Talzenna · 2019-03-23 · $620 Travel for Bavencio · 2019-01-21 · $53

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Hoffmann-La Roche Limited · Morpheus Breast · 2023	Their institution	$561,025
Hoffmann-La Roche Limited · Morpheus Breast Cancer · 2024	Their institution	$544,128
Hoffmann-La Roche Limited · Morpheus Breast · 2022	Their institution	$529,545
PFIZER INC. · An Interventional Openlabel Randomized Multicenter Phase 3 Study of Pf07220060 Plus Letrozole Compared To Cdk46 Inhibitor Plus Letrozole in Participants Over 18 Years of Age With Hormone Receptor Hrpositive Her2negative Advancedmetastatic Breast Cancer Who Have Not Received Any Prior Systemic Anticancer Treatment for Advancedmetastatic Disease Fourlight3 · 2025	Their institution	$525,882
Hoffmann-La Roche Limited · Morpheus Breast Cancer · 2025	Their institution	$475,684
PFIZER INC. · An Interventional Safety and Efficacy Phase 1b2 Openlabel Study To Investigate Tolerability Pk and Antitumor Activity of Vepdegestrant Arv471pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Pf07220060 in Participants Aged 18 Years and Older With Erher2 Advanced Or Metastatic Breast Cancer · 2025	Their institution	$410,444
BioNTech SE · 2025	Their institution	$404,018
PFIZER INC. · A Phase II Clinical Trial of Bmn 673 in Brca12 Wildtype Patients With 1 Advanced Tnbc Homologous Recombination Deficiency As Assessed By the Hrd Assay · 2019	Their institution	$401,050
Hoffmann-La Roche Limited · Morpheus Breast Cancer · 2023	Their institution	$322,794
PFIZER INC. · A Phase II Clinical Trial of Bmn 673 in Brca12 Wildtype Patients With 1 Advanced Tnbc Homologous Recombination Deficiency As Assessed By the Hrd Assay · 2023	Their institution	$274,222
Hoffmann-La Roche Limited · Morpheus Breast · 2024	Their institution	$272,162
PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy A Arv471 in Combination With Abemaciclib · 2024	Their institution	$264,153
Merck Sharp & Dohme Corporation · A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Intravenous Pembrolizumab Therapy in Patients With Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer · 2021	Their institution	$234,000
Bayer HealthCare Pharmaceuticals Inc. · A Multicenter Non-Randomized Open-Label Phase 1b Study To Determine the Maximum Tolerated and Recommended Phase 2 Dose of the Atr Inhibitor Bay 1895344 in Combination With Pembrolizumab and To Characterize Its Safety Tolerability Pharmacokinetics and Preliminary Anti-Tumor Activity in Patients With Advanced Solid Tumors · 2020	Their institution	$223,774
Genentech, Inc. · Phase 3 Study of Anti Pdl1 With Abraxane in Tn Mbc · 2019	Their institution	$222,916
PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy B Arv471 in Combination With Ribociclib · 2025	Their institution	$216,891
Merck Sharp & Dohme Corporation · A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Intravenous Pembrolizumab Therapy in Patients With Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer · 2019	Their institution	$194,400
Genentech, Inc. · A Study of Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in Neoadjuvant Etnbc · 2020	Their institution	$181,689
Genentech, Inc. · A Study of Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in Neoadjuvant Etnbc · 2019	Their institution	$175,425
Merck Sharp & Dohme LLC · Explore the Efficacy and Safety of Pembrolizumab and Photodynamic Therapy in Metastatic Esophageal Squamous Cell Carcinoma Failed at Least One Line of Systemic Treatment · 2024	Their institution	$169,420
PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy A Arv471 in Combination With Abemaciclib · 2023	Their institution	$153,104
Hoffmann-La Roche Limited · Morpheus Breast · 2021	Their institution	$151,847
PFIZER INC. · A Phase 1b2 Study To Evaluate Safety and Anti Tumor Activity of Avelumab in Combination With the Polyadenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Locally Advanced Or Metastatic Solid Tumors · 2020	Their institution	$146,261
Bayer HealthCare Pharmaceuticals Inc. · A Multicenter Non-Randomized Open-Label Phase 1b Study To Determine the Maximum Tolerated and Recommended Phase 2 Dose of the Atr Inhibitor Bay 1895344 in Combination With Pembrolizumab and To Characterize Its Safety Tolerability Pharmacokinetics and Preliminary Anti-Tumor Activity in Patients With Advanced Solid Tumors · 2021	Their institution	$144,307
Hoffmann-La Roche Limited · Morpheus Tnbc · 2023	Their institution	$142,912
Genentech, Inc. · A Phase III Multicenter Randomised Double Blind Placebo Controlled Study of Atezolizumab · 2021	Their institution	$138,689
Merck Sharp & Dohme LLC · A Phase 1 Study of Hmbd-002-V4c26 Hmbd-002, A Monoclonal Antibody Targeting Vists, As Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies · 2024	Their institution	$133,960
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2 Breast Cancer Keynote-756 · 2021	Their institution	$133,634
Merck Sharp & Dohme Corporation · A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Intravenous Pembrolizumab Therapy in Patients With Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer · 2020	Their institution	$129,600
PFIZER INC. · A Phase 1b2 Study To Evaluate Safety and Anti Tumor Activity of Avelumab in Combination With the Polyadenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Locally Advanced Or Metastatic Solid Tumors · 2019	Their institution	$129,092
EMD Serono, Inc. · 2019	Their institution	$127,738
Hoffmann-La Roche Limited · Morpheus Breast · 2020	Their institution	$125,154
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2- Breast Cancer Keynote-756 · 2020	Their institution	$112,168
PFIZER INC. · An Interventional Safety and Efficacy Phase 1b2 Openlabel Study To Investigate Tolerability Pk and Antitumor Activity of Vepdegestrant Arv471pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Pf07220060 in Participants Aged 18 Years and Older With Erher2 Advanced Or Metastatic Breast Cancer · 2024	Their institution	$110,884
PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy B Arv471 in Combination With Ribociclib · 2023	Their institution	$107,577
PFIZER INC. · A Phase II Trial of Talazoparib Monotherapy for Palb2 Mutationassociated Advanced Breast Cancer · 2021	Their institution	$100,000
PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy B Arv471 in Combination With Ribociclib · 2024	Their institution	$96,526
Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Phase 2 Study of Imprime Pgg and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-Line Treatment With Checkpoint Inhibitors Cpi Or Triple Negative Breast Cancer Tnbc Failing Front-Line Chemotherapy for Metastatic Disease · 2019	Their institution	$91,800
PFIZER INC. · A Phase 1b2 Study To Evaluate Safety and Anti Tumor Activity of Avelumab in Combination With the Polyadenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Locally Advanced Or Metastatic Solid Tumors · 2022	Their institution	$80,545
Merck Sharp & Dohme LLC · A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Intravenous Pembrolizumab Therapy in Patients With Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer · 2022	Their institution	$78,000
Genentech, Inc. · A Phase III Multicenter Randomised Double Blind Placebo Controlled Study of Atezolizumab · 2019	Their institution	$74,623
PFIZER INC. · Phase 2 Study in Patients With Neoadjuvant Breast Cancer · 2020	Their institution	$73,770
Merck Sharp & Dohme LLC · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2 Breast Cancer Keynote-756 · 2022	Their institution	$73,467
PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Vepdegestrant Arv471pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 and Older With Er Advanced Or Metastatic Breast Cancer Substudy C Arv471 in Combination With Samuraciclib · 2025	Their institution	$69,519
PFIZER INC. · Phase 2 Study in Patients With Neoadjuvant Breast Cancer · 2019	Their institution	$62,280
Genentech, Inc. · Phase 3 Study of Anti Pdl1 With Abraxane in Tn Mbc · 2020	Their institution	$55,442
PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Vepdegestrant Arv471pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 and Older With Er Advanced Or Metastatic Breast Cancer Substudy C Arv471 in Combination With Samuraciclib · 2024	Their institution	$52,296
SANOFI US SERVICES INC. · A Phase 1/2 Study To Evaluate the Safety, Pharmacokinetics, and Efficacy of Blu-222 As A Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors · 2025	Their institution	$47,575
Blueprint Medicines Corporation · A Phase 1/2 Study To Evaluate the Safety, Pharmacokinetics, and Efficacy of Blu-222 As A Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors · 2025	Their institution	$36,814
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2- Breast Cancer Keynote-756 · 2019	Their institution	$33,582
Hoffmann-La Roche Limited · Morpheus Tnbc · 2022	Their institution	$32,647
Genentech, Inc. · Phase 3 Study of Anti Pdl1 With Abraxane in Tn Mbc · 2021	Their institution	$32,225
Merck Sharp & Dohme LLC · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2 Breast Cancer Keynote-756 · 2023	Their institution	$30,936
GlaxoSmithKline, LLC. · A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and S · 2023	Their institution	$30,409
GlaxoSmithKline, LLC. · A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and S · 2022	Their institution	$27,852
Blueprint Medicines Corporation · A Phase 1/2 Study To Evaluate the Safety, Pharmacokinetics, and Efficacy of Blu-222 As A Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors · 2024	Their institution	$27,316
Hoffmann-La Roche Limited · Morpheus Breast · 2025	Their institution	$25,507
Genentech, Inc. · A Study of Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in Neoadjuvant Etnbc · 2021	Their institution	$22,817
TESARO, Inc. · Phase 12 Clinical Study of Niraparib in Combination With Pembrolizumab in Patients With Advanced Or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer · 2019	Their institution	$22,521
GlaxoSmithKline, LLC. · Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizuma · 2020	Their institution	$22,389
Merck Sharp & Dohme Corporation · A Multicenter, Open-Label, Phase 2 Study of Imprime Pgg and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-Line Treatment With Checkpoint Inhibitors Cpi Or Triple Negative Breast Cancer Tnbc Failing Front-Line Chemotherapy for Metastatic Disease · 2020	Their institution	$21,600
PFIZER INC. · A Phase 1b2 Study To Evaluate Safety and Anti Tumor Activity of Avelumab in Combination With the Polyadenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Locally Advanced Or Metastatic Solid Tumors · 2021	Their institution	$20,800
AbbVie, Inc. · 2019	Their institution	$18,170
Genentech, Inc. · 1l Mtnbc Ipatasertib Tecentriq Paclitaxel · 2020	Their institution	$17,856
PFIZER INC. · Tactiveu An Interventional Safety and Efficacy Phase 1b2 Openlabel Umbrella Study To Investigate Tolerability Pk and Antitumor Activity of Arv471 Pf07850327 An Oral Proteolysis Targeting Chimera in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With Er Advanced Or Metastatic Breast Cancer Substudy A Arv471 in Combination With Abemaciclib · 2025	Their institution	$17,698
Merck Sharp & Dohme LLC · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2- Breast Cancer Keynote-756 · 2024	Their institution	$17,395
EMD Serono, Inc. · An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Vx-970/M6620 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors · 2020	Their institution	$16,833
MEDIVATION INC. · A Phase 3 Openlabel Randomized Parallel2armmulticenter Study of Talazoparibbmn 673 Versus Physicians Choice in Germline Brca Mutation Subjects With Locally Advanced Andor Metastatic Breast Cancer Who Have Received Prior Chemotherapy Regimens for Metastatic Disease · 2019	Their institution	$15,761
GlaxoSmithKline, LLC. · A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and S · 2024	Their institution	$15,533
PFIZER INC. · A Phase II Trial of Talazoparib Monotherapy for Palb2 Mutationassociated Advanced Breast Cancer · 2023	Their institution	$14,420
Genentech, Inc. · A Phase III Multicenter Randomised Double Blind Placebo Controlled Study of Atezolizumab · 2020	Their institution	$14,395
Merck Sharp & Dohme LLC · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re · 2025	Their institution	$13,156
PFIZER INC. · Talazoparib Clinical Publication Program · 2022	This clinician	$12,880
Merck Sharp & Dohme LLC · A Phase 1 Study of Hmbd-002-V4c26 Hmbd-002, A Monoclonal Antibody Targeting Vists, As Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies · 2023	Their institution	$10,650
PFIZER INC. · The Compassher2 Trials Comprehensive Use of Pathologic Response Assessment To Optimize Therapy in Her2positive Breast Cancer Compassher2 Residual Disease Rd A Doubleblinded Phase III Randomized Trial of Tdm1 Compared With Tdm1 and Tucatinib · 2024	Their institution	$10,000
ABBVIE INC. · A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin To Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (Tnbc) · 2021	Their institution	$7,296
Hoffmann-La Roche Limited · Morpheus Tnbc · 2024	Their institution	$6,080
AbbVie Inc. · 2020	Their institution	$6,028
PFIZER INC. · Talazoparib Clinical Publication Program · 2021	This clinician	$5,420
MEDIVATION INC. · A Phase 3 Openlabel Randomized Parallel2armmulticenter Study of Talazoparibbmn 673 Versus Physicians Choice in Germline Brca Mutation Subjects With Locally Advanced Andor Metastatic Breast Cancer Who Have Received Prior Chemotherapy Regimens for Metastatic Disease · 2020	Their institution	$5,120
PFIZER INC. · Talazoparib Clinical Publication Program · 2023	This clinician	$3,300
F. Hoffmann-La Roche AG · A Phase III Randomized Study To Investigate the Efficacy and Safety of Atezolizumab Anti-Pd-L1 Antibody in Combination With Neoadjuvant Anthracycline-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer · 2020	This clinician	$3,183
F. Hoffmann-La Roche AG · Morpheus Breast Cancer · 2023	This clinician	$2,847
AbbVie, Inc. · 2019	This clinician	$2,841
Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2021	Their institution	$2,780
PFIZER INC. · A Phase 2 Non Randomized Open Label Single Arm Multi Center Study of Talazoparib for Neoadjuvant Treatment of Germline Brca12 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer · 2021	Their institution	$2,467
GlaxoSmithKline, LLC. · A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and S · 2025	Their institution	$2,381
G1 Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind Study of Cosela Or Placebo in Patients Receiving First- Or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer (Preserve-2) · 2022	This clinician	$1,513
F. Hoffmann-La Roche AG · A Study of Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in Neoadjuvant Etnbc · 2025	This clinician	$1,386
G1 Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind Study of Trilaciclib Or Placebo in Patients Receiving First- Or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer (Preserve-2) · 2023	This clinician	$1,056
F. Hoffmann-La Roche AG · Safety and Feasibility of Phase1b Ipatasertib Plus Atezolizumab Plus Chemo in 1st Line Met Tnbc · 2021	This clinician	$816
Immunomedics, Inc. · Immu-132-09 · 2020	This clinician	$525
MEDIVATION INC. · A Phase 2 2stage 2cohort Study of Talazoparib Bmn 673 Administered To Germline Brca Mutation Subjects With Locally Advanced Andor Metastatic Breast Cancer · 2019	Their institution	$448
Merck Sharp & Dohme LLC · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2023	Their institution	$435
BioNTech SE · 2024	Their institution	$194
Merck Sharp & Dohme LLC · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2022	Their institution	$150

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 76.5 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1932135290
Licence: CA A84689California A84689: Current · expires 2027-09-30
Trained: George Washington University School of Medicine, 2002
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Medical oncology (207RX0202X); Internal medicine (207R00000X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2006-06-25
NPI last updated: 2024-04-25
NPI record certified: 2024-04-17

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 875 Blake Wilbur Dr, Stanford, CA, 94305